Published in final edited form as:

Mol Neurobiol. 2019 April ; 56(4): 2618–2639. doi:10.1007/s12035-018-1262-y.

The role of deimination in regenerative reprogramming of neurons

Di Ding¹, Mabel Enriquez-Algeciras¹, Anddre Osmar Valdivia¹, Juan Torres¹, Cameron Pole¹, John W. Thompson³, Tsung-han Chou¹, Miguel Perez-Pinzon^{2,3}, Vittorio Porciatti¹, Susan Udin⁴, Eric Nestler⁵, and Sanjoy K. Bhattacharya^{1,2,*}

¹Bascom Palmer Eye Institute, University of Miami, Miami, Florida, USA

²Neuroscience Program, University of Miami, Miami, Florida, USA

³Department of Neurological Surgery, University of Miami, Miami, Florida, USA

⁴Department of Physiology and Biophysics, State University of New York, Buffalo, New York, USA

⁵Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Abstract

Neurons from the adult central nervous system (CNS) demonstrate limited mRNA transport and localized protein synthesis versus developing neurons, correlating with lower regenerative capacity. We found that deimination (posttranslational conversion of protein-bound arginine into citrulline), undergoes up-regulation during early neuronal development while declining to a low basal level in adults. This modification is associated with neuronal arborization from amphibians to mammals. The mRNA binding proteins (ANP32a, REF), deiminated in neurons, have been implicated in local protein synthesis. Overexpression of the deiminating cytosolic enzyme peptidyl arginine deiminase 2 in nervous systems results in increased neuronal transport and neurite outgrowth. We further demonstrate that enriching deiminated proteins rescues transport

*Correspondence should be addressed to: Sanjoy K. Bhattacharya, University of Miami, Department of Ophthalmology, 1638 N.W. 10th Avenue, #706, Miami, FL 33136, sbhattacharya@med.miami.edu.

Di Ding, University of Miami, Department of Ophthalmology, 1638 N.W. 10th Avenue, #706, Miami, FL 33136, DDing@med.miami.edu

Mabel Enriquez-Algeciras, University of Miami, Department of Ophthalmology, 1638 N.W. 10th Avenue, #706, Miami, FL 33136, malgeciras@med.miami.edu

Anddre Osmar Valdivia, University of Miami, Department of Ophthalmology, 1638 N.W. 10th Avenue, #706, Miami, FL 33136, Aov7@med.miami.edu, ORCID: 0000-0002-8425-9102

Juan Torres, University of Miami, Department of Ophthalmology, 1638 N.W. 10th Avenue, #706, Miami, FL 33136, jetch2011@gmail.com

Cameron Pole, University of Miami, Bascom Palmer Eye Institute/Neuroscience Program/Miami Biomedical Engineering, Program, Miami, FL 33136, cpole82190@gmail.com

John W. Thompson, University of Miami, Neurological Surgery 6 –STA, Miami, FL 33136, JThompson@med.miami.edu

Tsung-han Chou, University of Miami, Bascom Palmer Eye Institute/Neuroscience Program/Miami Biomedical Engineering, Program, Miami, FL 33136, TChou@med.miami.edu

Miguel Perez-Pinzon, University of Miami, Department of Neurology, Miami, FL 33136, perezpinzon@med.miami.edu

Vittorio Porciatti, University of Miami, Bascom Palmer Eye Institute/Neuroscience Program/Miami Biomedical Engineering, Program, Miami, FL 33136, 305-326-6050, VPorciatti@med.miami.edu

Susan Udin, State University of New York, Buffalo, Department of Physiology and Biophysics, 553 Biomedical Res. Building, Buffalo, NY 14214, susan.udin@gmail.com

Eric Nestler, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1065, New York, NY 10029, eric.nestler@mssm.edu

Sanjoy K. Bhattacharya, University of Miami, Department of Ophthalmology, 1638 N.W. 10th Avenue, #706, Miami, FL 33136, sbhattacharya@med.miami.edu

Conflict of Interest:

The authors declare that they have no conflict of interest.

deficiencies both in primary neurons and mouse optic nerve even in the presence of pharmacological transport blockers. We conclude that deimination promotes neuronal outgrowth via enhanced transport and local protein synthesis and represents a new avenue for neuronal regeneration in the adult CNS.

Keywords

Deimination; Regeneration; Development; PAD2

Introduction

The delivery of cargo to specific compartments within the neurons is critical for establishing unique cellular domains and plays a crucial role during development and synapse formation [1]. During these processes, local mRNA synthesis becomes a heavily regulated process mediated by motor, adaptor, and scaffolding proteins that regulate mRNA transport to specific compartments [1,2]. Cargo destined for specific compartments is transported based upon the unique association with compartment-specific motor complexes whose specific complexation occurs before axonal specification [2]. Hence, defects of motor proteins that are involved in this transport system have been demonstrated to be associated with neuronal degeneration [3–7]. The mammalian peripheral nervous system (PNS) maintains the ability to regenerate into adulthood [8–10], whereas neurons of the central nervous system (CNS) are incapable of regeneration [11,12,6] therefore, the loss of regenerative capacity has been attributed to be the result of reduced levels of translational machinery and growth inhibitors that prevent protein synthesis following injury in the mature CNS [3,6,7,13].

Compartmental local protein synthesis by means of RNA trafficking has been reported in dendrites in neuronal cultures [8] and several independent studies have now corroborated selective trafficking of mRNA and their local translation in specific neuronal compartments [9,10,12,11]. Despite these demonstrations, restoration of protein synthesis and transport in mature neurons that promote neuronal growth remains a challenge [3]. In addition, the mechanisms that promote neuronal transport through the selection of cargoes and their interactions with motor proteins (which lead to the distribution of mRNA and local proteins synthesis) remain poorly understood. Post-translational modifications (PTMs) such as deimination (the conversion of protein-bound arginine into citrulline) are another layer of regulatory mechanisms that remains to be explored [14]. Due to the lack of a bona-fide reversal enzyme, deimination is considered to be an irreversible and long term PTM whose longevity highlights its potential for long term regulatory effects. Thus far, only a limited number of proteins have been identified to undergo deimination [15] however, deimination is highly regulated in different cell types, and dysregulation of deimination has been reported in neurodegenerative diseases such as multiple sclerosis and glaucoma [16–18]. Here, we demonstrate that deimination regulates interaction of cargo molecules and molecular motors, suggesting that neuronal transport affects neurite outgrowth and neuronal function in vitro and in vivo [11].

Results

Deimination level is associated with neuronal outgrowth

Deimination has been observed in the Infant CNS which showed higher levels of deimination when compared to adult brains [19] in addition, deimination has been documented to decreased in aged rats when compared to young rats [20]. As deimination is under independent regulation in different cell types, the co-existence of hyper-deimination in astroglial cells and hypo-deimination in neurons of neurodegenerative diseases with inflammation [21] makes it difficult to observe deimination changes when neurons undergo degeneration. We utilized three different systems, ocular rotation in frogs, cocaine treatment in mice and neuronal cultures (in which the effects of deimination in glial cells are minimized) to analyze changes in neuron-specific deimination during neurite outgrowth and retraction. Ocular rotation in frogs results in new arborization (new neurite formation) in the optic tectum without activation of astroglial cells [22,23], rendering it a suitable model for detection of deimination in neurons without interference from glial cells. Neurons undergoing arborization were traced by cholera toxin subunit B. Immunohistochemical (IHC) analysis showed a significant increase in deimination in the contralateral tectal lobes of the rotated eyes compared to controls (Fig. 1a, b), commensurate with increased neurite outgrowth that co-localizing with neural arborization as indicated by tracer (Fig. 1a). These findings were further corroborated using Western blot analysis showing increased protein-bound citrulline (deimination) in the rotated eye of the contralateral tectal lobe (Fig. 1c). The increase in deimination was associated with increased expression of peptidyl arginine deiminase 2 (PAD2), the major cytoplasmic deiminase in neurons (Fig. 1c). Our second model was the chronic cocaine treated mouse cerebellum, which undergoes degeneration and neurite retraction [24], with no reported astroglial cell activation. In contrast to the eye-rotated frog optic tectums, PAD2 levels in the cerebellums of chronic cocaine-treated mice (C57BL/6J) showed a significant decrease when compared to the saline-treated controls (Fig. 1d–f). The reduction in PAD2 correlates with reduced axonal marker SMI312 and the synaptosomal protein SNAP-25, suggesting rearrangement of neurons (Fig. 1d–f).

We further investigated deimination levels in primary rat neurons cultures and in established neuronal cell lines (PC12 and Neuro2A) under neurite growth permissive and growth inhibitory conditions independently. PAD2 expression increased after 6 days in mouse primary neurons (E17) (Fig. 1g), commensurate with PAD2 mRNA increase during early development in the first week and decrease during adulthood (Fig. 1h). Nerve growth factor (NGF) was used to induce neurite growth in PC12 cells and primary neurons (Fig. 2a), while myelin basic protein (MBP) fragments were used as a growth inhibitor for Neuro 2A cells and primary neurons (Fig. 2b). As expected, PAD2 expression was up-regulated in NGF treated cells but decreased in MBP-treated cells/neurons (Fig. 2a–c). These results suggest that deimination levels are associated with neurite outgrowth and retraction. Early steps of neuronal compartmentalization are associated with polarized cargo trafficking, therefore subsequent experiments attempted to unravel the association between deimination and polarized trafficking.

Deimination is associated with polarized trafficking

Acidic nuclear phosphoprotein 32a (ANP32a) and RNA export factor (REF) are mRNA binding proteins, primarily localized in the nucleus [25,26], that are deiminated in neurons during normal conditions [18,21], but show a decreased in deimination in neurodegenerative diseases [21]. ANP32a and REF play a role in mRNA processing/export and neuronal differentiation respectively [27]. Deiminated REF facilitates the transport of mRNAs such as ATP5b and SNAP-25, resulting in their increased dendritic synthesis [18,21]. Although PAD2 expression levels lacks correlation with the expression levels of REF and ANP32a (Fig. 1g, 2a–c) we found that ANP32a is transported in a polarized manner in neurons and consistently co-localizes with the deimination signal (Fig. 2d). Disruption of deimination by PAD2 knockdown with shRNA abolished ANP32a polarization (Fig. 2d), indicating a role of deimination in its transport.

Proteins and their interactors under regulation of deimination

REF and ANP32a were detected in the pool of PAD2 interactors by immunoprecipitation (IP) (Fig. 3a). In contrast, molecular motors dynactin (DCTN) and KIF21b were not deiminated and as such were not pulled down by PAD2. REF was found to associate with dynactin and kinesins (KIF21b and KIF5A) from reciprocal IPs with different motor proteins (Fig. 3b), indicating that PAD2 is likely indirectly interacting with motor proteins through REF. More extensive mass spectrometric analysis identified several PAD2 pulled down proteins that are related to ribonucleoproteins (RNPs) and RNA granules (Table 1), suggesting that PAD2 plays a role in the mechanism of mRNA transport.

To determine deiminated REF interactors, non-deiminated REF recombinant proteins were produced in *E. coli* (lacks deiminase), and a fraction was in vitro deiminated by adding purified PAD2. Equal amounts of non-deiminated (control) and deiminated REF were used to pull down interactors in neuronal cells. Deiminated REF associated with different cohorts of RNA processing proteins (Fig. 3c), suggesting that deiminated REF may play a role as a specialized mRNA transporter that likely exhibits unique cargo selection depending on the cell compartment.

Increased PAD2 levels induced by viral vector expression in primary neurons promoted neurite elongation (Fig. 3d–f), up-regulation and accumulation of end products GTPase Rab3 and SNAP-25 proteins (Fig. 3f). Simultaneously, increased ANP32a was found in neurites but not within the cell bodies (Fig. 3d–f), which coincided with elevated arborization. In contrast, PAD2 knock down showed a shift in distribution of SNAP-25, ANP32a, and dynein in the cell body and neurites (Fig. 3f). Taken together these results suggest that deimination is involved in regulation of trafficking of specific proteins. We next investigated transport of cargo via molecular motors.

Association of deiminated molecules and PAD2 with motors systems

PAD2 expression is related to neuronal growth and associated with mRNA binding proteins such as ANP32a and REF, which in turn facilitates interaction with motor proteins (such as KIF21b and KIF5A). We questioned whether the transport and localized translation in different neuronal compartments facilitated by ANP32a and REF are the intrinsic neurite/

neuronal growth mechanisms. To address this, we tested whether there is a shift in subcellular localization of specific mRNAs or proteins, or an overall increase in their levels with regulation of PAD2 expression. We utilized novel neuronal fractionation for compartmental level analyses. Laser capture microdissection (on unfixed tissues to preserve proteins) suitable to fractionate different compartments of neurons generated insufficient quantities of reproducible material to perform multiple biochemical analyses in our repeated trials. Therefore, we developed a new fractionation method using biotin conjugated lectins (proteins that binds to sugars on cell surface proteins). We found two plant lectins, [*Canavalia ensiformis* (designated as lectin 2) and *Maclura pomifera* (lectin 3)], that preferentially associated with neurites and the neuronal cell body respectively (Fig. 4a). The lectin-bound neurons incubated with streptavidin-coupled magnetic beads allowed fractionation of neuronal compartments (described in method). The eluents from purification steps were loaded onto a gel and their cellular compartmental location determined by the markers Tau1 and GAPDH (Fig. 4a). The purity of the fractions was further evaluated by probing the blots for the cytoplasmic GAPDH and the synaptic marker SNAP-25. This approach allowed detection of the compartmental locations of PAD2 and ANP32/REF. The majority of REF was located within the neurites rather than the cell body (Fig. 4b). KIF21b, mainly localized to neurites, while dynactin was ubiquitous throughout both fractions (Fig. 4b). Increased PAD2 expression results in increased SNAP-25 and dynein levels and a shift in dynein localization from the cell body to neurites – an opposite effect from that observed when PAD2 expression was inhibited (Fig. 4c). We further determined if REF or ANP32a had a unique subset of interactors in different neuronal fractions using IP-mass spectrometry (Table 2). Some interactors are parts of RNP or RNA granules, both of which are enriched in neurites. We determined whether there are any differences between REF/ANP32a (both RNA binding proteins) and the associated repertoire of mRNA in neurites and cell bodies of the neuron (Fig. 4d). ANP32a had a higher affinity for most mRNA in the cell body. However, REF had higher affinities for Sphk2 (Sphingosine Kinase 2) and Capza2 (F-Actin Capping Protein Alpha-2 Subunit) mRNAs in the neurites than in other compartments, indicating that REF transport would change the distribution for these mRNAs. Whether deimination would affect the distribution of the selected mRNA was tested by overexpressing and knocking-down PAD2 expression. As expected, mRNA such as Camk2a, STX3, CaMK1, Capza1 had different distributions between cell body and neurites when the level of deimination changed (Fig. 4e). These differences could be regulated by the transport of either REF or ANP32a. It has been established that distribution of STX3 and several other mRNAs are regulated through their untranslated (UTR) regions by RNA binding proteins [21,28,29]. To study transport and translation, we developed a hybrid construct that has 5', 3' UTR regions of STX3 and mCherry and a construct of REF fused with GFP (see methods for details). In cortical neurons that were co-infected with virus containing the two constructs, STX3 and REF colocalized in the axons (Fig. 5b bottom panels). In order to observe the translation of STX3, STX3-mCherry signals (Fig. 5b, top panels) was bleached at wavelength 546, where REF signal stays unaffected (Fig. 5b middle panels). During the 4 minutes recovery time, mCherry (STX3 UTR) with REF signal perfectly colocalized and moved towards the axon, suggesting REF is associated with STX3 during transport and translation. In comparison with neurons without REF overexpression, STX3 proteins took longer time to recover after bleaching, indicating the REF plays a role in transport and

translation (Fig. 5a). In summary, these results suggest that PAD2 regulates mRNAs transport and protein translation through modification of REF and ANP32a. Moreover, their locations within neuronal compartments were found to closely related to their deimination level.

Next, we questioned how PAD2 would affect neuronal transport, which required a model system for direct visualization of motor transport. In order to label live neurons without disrupting their activity, we looked at small molecules that specifically interact with motor proteins and can be easily introduced into the cell. For this application, lipid molecules are ideal candidates (Fig. 6a), and some lipids showed specificity to the motor systems (Fig. 6b). To identify the lipids that associate with different motors, we performed IPs against different motor proteins followed by lipid identification from the eluent (Fig. 6c). This approach identified several lipids which were motor specific, such as binding to KIF21b but not KIF5a, allowing to distinguish between anterograde and retrograde transport. A custom fluorescent lipid probe was designed from one of the candidates (a glycolipid, FMC-5(d18:1/20:0)), synthesized commercially, and tested on neurons. There was a time dependent decrease in axonal fluorescence, suggesting that this lipid was associated with retrograde transport in contrast to a control (phosphatidylserine) lipid (Fig. 6a). We used this approach to further evaluate the effects of deimination on neuronal transport. Primary neurons (E17), grown in an axon isolation chamber [27] (that contains microgrooves to guide neurite growth) were subjected to elevation in deimination by viral vector mediated PAD2 expression. Two neuronal transport blockers (lidocaine and vincristine) were used to interrupt neuronal transport concurrent with overexpressed PAD2 or control [30,31]. Fluorescent lipid probes were detected using live imaging. As shown in Fig. 6d and 6e (Movie 1 and 2), transport in the control cells was stalled within 30 min of adding lidocaine or vincristine; however, transport was still active in the presence of overexpressed PAD2. These results suggest that deimination is involved in regulation of specific cargo transport via specific molecular motors.

The effect of deimination in neuronal transport in a mouse model

Next we attempted to determine if pharmacological perturbations can relate deimination and neuronal transport to a functional visual (neuronal) outcome using an in vivo model system. Pattern electroretinograms (PERGs) primarily reflect the functional integrity of retinal ganglion cells (RGCs), including their signal transport and connectivity. Lidocaine can reduce PERG amplitude by blocking axonal retro-transport [32]. Here, we utilized a hybrid ND4(H), a cross between SLICK-H (genetically engineered mouse to express enhanced yellow fluorescent protein (EYFP) under regulation of the Thy1 promoter, rendering for a ready and easy visualization of dendrites (arbor) in a broad subset of neurons) [33] and ND4 (model for multiple sclerosis) mice [34,35]. The hybrid ND4(H) mouse strain demonstrates the presence of the Thy1 marker in neuronal cells (Fig. 7d). To determine whether deimination would rescue transport under conditions where normal axonal transport is interrupted, we increased vector mediated PAD2 expression in retinas. PERG measurement showed that PAD2 overexpression maintained up to 40% of baseline amplitude after lidocaine injection/inhibition and was significantly different from controls (without PAD2 overexpression) that lacked a visible wave (Fig. 7a–c). Western blots (Fig. 8a) showed

increased expression of SNAP-25 in eyes overexpressing PAD2 (Fig. 8c), suggesting that deimination facilitates the maintenance of the PERG wave by increasing neuronal transport. After 2 weeks, the eyes with PAD2 expression demonstrated stronger Thy1 signals compared to the control eyes (Fig. 7d, e).

Discussion

There is growing recognition of the presence of quiescent neurons that are not being used in full capacity [36,37], and their potential regenerative connectivity with targets in neighboring neurons which could allow them to be functionally restorative. Intuitively, increased transport should enhance protein biosynthesis, neurite growth, and connectivity; which are all hallmark of neurodegeneration when they decrease. Graft experiments suggest that this can be reversed in the adult phase [3] and the evidence presented here suggests that normalization of deimination is one such regulatory mechanism to increase molecular transport, protein biosynthesis, and regenerative re-connectivity in lower vertebrates/amphibians (Fig. 1) and mammals (Fig. 1 and 7).

The intrinsic high rate of transport and translation underlie maintenance of neural growth during development [38–40] which is substantially lost in adulthood, particularly in the CNS [12,9,6,41,42]. In adults, increased cargo transport and protein synthesis at the correct neuronal compartment/location are necessary for recovery from degeneration [43,44,41]. In contrast to the PNS, CNS neurons are restricted by the surrounding environment. Intrinsic regulation that increases the rate of transport and protein synthesis may overcome inhibition and result in functional restoration [3].

Long term and irreversible PTMs, such as deimination [14], are important but under-investigated regulators. In neuronal tissues, deimination shows a complexity of regulation in a cell specific manner [17,20]. Loss of deimination precedes the loss of visual function [21] and also modulates organelle mRNA transport [18]. We show here that increased and decreased deimination are associated with neuronal outgrowth (Fig. 1a) and retraction (Fig. 1d), respectively, suggesting that normalization of deimination levels may promote neurite outgrowth even in adults. Up- and down-regulation of PAD2 affects REF deimination, distribution of REF-associated mRNAs, and timed cargo accumulation by molecular motors such as KIF21b and dynein/dynactin (Fig. 4c, e). The assembly of RNA granules and their transport are promoted by deimination from PAD2 overexpression (Fig. 3c, 4c, 4e). Conversely, down-regulation of PAD2 using siRNA shows decreased neurite outgrowth (Fig. 2d) and that using shRNA against PAD2 shows decreased transport of mRNA cargo molecules (Fig. 4e). REF facilitates the delivery of specific mRNAs to their target cellular compartments to enhance local protein synthesis (Fig. 5), as depicted in our model shown in Fig. 8e. PAD2 overexpression resulted in increased cargo transport (Fig. 3a, b, Fig. 4e) that could overcome inhibition by the transport blockers lidocaine and vincristine (Fig. 6d, e). Normalization of deimination thus enhanced compartmental protein synthesis (Fig. 4b, c). Deimination-induced regenerative neurite outgrowth in adults (Fig. 1a, b) appeared to underlie functional visual restoration (Fig. 7, 8). Neuronal trafficking and localized protein synthesis are highly regulated and intrinsic to neuronal activity [45]. We developed innovative fractionation methods to probe transported molecules in different neuronal

compartments (Fig. 4–6), and our techniques included using motor-associated, fluorophore-conjugated lipids as indicators of motor movement. Many neurodegenerative diseases such as glaucoma [46], Alzheimer's disease, and demyelinating diseases [47–49], are associated with impaired axonal transport, the reversal of which may enhance neurite outgrowth [50] and lead to the restoration of visual function (Fig. 7, 8). The proposed mechanism of deimination as one of the intrinsic regulators of recalibrating regenerative connectivity could be a new direction for functional restoration.

Materials and Methods

Animals

All animal protocols were approved by the Animal Care and Use Committee of the University of Miami or of the University at Buffalo. The original breeding pairs of ND4 mice were mice from The Hospital for Sick Children, Toronto, Canada as a research gift, and a pathogen-free line was derived via embryo transfer performed at the Charles River Laboratory (Wilmington, MA). After confirmation of the genetic status, a colony was maintained at Bascom Palmer Eye Institute. Breeding pairs of SLICK mice were purchased from Jackson Lab (Bar Harbor, MA). Hybrids of ND4 mouse strains (ND4(H)) were derived from a cross between SLICK and ND4 mice. The sparse YFP labeling (Thy1-YFP) in these derivatives were confirmed by confocal scanning laser ophthalmoscopy (CSLO) imaging. All mice were maintained in the McKnight vivarium at the University of Miami.

Xenopus eye rotation

Xenopus laevis tadpoles were obtained from Xenopus1, Dexter, MI. Nieuwkoop and Faber stage 56–57 tadpoles were anesthetized by immersion in 1:4000 MS-222 in 10% Holtfreter's solution [51]. The skin dorsal to the left eye was opened with fine forceps, and the extraocular muscles were pinched apart. The eye was rotated 90° around the optic nerve. At two month post-metamorphosis, the frogs were anesthetized by subcutaneous injection with 1% MS-222 in 10% Holtfreter's solution, and the brains were fixed by immersion in 4% paraformaldehyde.

Cell culture

PC12 cells and Neuro-2A cells were purchased from ATCC (Manassas, VA). PC12 Cells were grown in Dulbecco's modified Eagle's medium (DMEM, Cellgro, Manassas, VA), supplemented with 10% horse serum (ATCC), 5% fetal bovine serum (Cellgro), and Neuron-2A cells were grown in DMEM (Cellgro), supplemented with 10% bovine serum (ATCC).

Primary cortical neuron-only cultures were prepared as previously described [52,53] from the cortices of E18–19 day pups. The embryos were harvested through a caesarian section and the cortices rapidly dissected from the brain and placed in ice cold HBSS. After removal of cerebral membranes, the cortices were enzymatically digested with 0.25% Trypsin-EDTA (Life Technologies) for 15 min at 37 °C. The resulting cellular suspension was filtered through a 70 µm filter and plated in MEM supplemented with 5% FBS, GlutaMax (Invitrogen/Life Technologies) and 15 mM glucose. The cells were plated on poly-D-lysine

coated coverslips at a density of 3,000 cells/coverslip or on poly-D-lysine coated 10 cm culture dish at a density of 50,000 cells.

Virus construct and PAD2 expression in animal eyes

The Thy1 promoter region is located 2000 bp upstream of the Thy1 start codon. The sequence was identified using UCSC Genome Bioinformatics database. The BAC clone with the insert of genomic DNA covering this region was obtained from Children's Hospital Oakland Research Institute (CHORI). Primers (Forward: 5'-AAAAAAACGCGTAATCCAGTCCAGAAATGGGGGTG; Reverse: 5'-GTGGGGGCTAGCGGACAAAGAAACTGCACAATA) including restriction sites for MluI and NheI were prepared to amplify the region 0–2000 bp upstream of the Thy1 start codon. PCR products were subjected to verification by agarose gel electrophoresis. The PCR bands were excised and extracted from the agarose gel using a QIAGEN Gel Extraction Kit (Qiagen, Valencia, CA). The concentration of gel purified DNA was determined using a UV/visible spectrophotometer. The insert and vector (pLionII) were simultaneously digested using restriction enzymes for excision of the CMV region on the vector. The digested inserts and pLionII were again subjected to gel electrophoresis, and were extracted using the gel extraction kit. The vector was dephosphorylated with calf intestinal alkaline phosphatase (CIP). The digested vector and insert DNA were ligated in a ratio of 1:3 by incubating with T4 ligase at 37°C for 2 hours. The ligated constructs were used for transformation of TOP10 competent *E. coli* cells. The colonies of transformants were picked, and isolated DNA was confirmed for the presence of the insert by double digestion of the plasmid. The construct was further confirmed by DNA sequencing. The Thy1-containing pLionII was further subjected to digestion with PmeI and NotI restriction enzymes. PAD2 was amplified using the clone vector (Open Biosystem) with primers (Forward: 5'-ATATAAGTTTAAACATGCTGCGCGAGCGGACCG; Reverse 5'-TTTTGCGGCCGCTTACAGAGGAAAGCTGCTC) containing the PmeI and NotI restriction sites. PAD2 was ligated with the Thy1-pLionII vector using the same procedure as above.

Virus production and transfection

Thy1-PAD2 pLionII and CMV-YFP pLionII constructs were transfected separately to human embryonic kidney (HEK-293) cells using FuGENE 6 Transfection Reagent (Roche). Briefly, structural vector (pCI-VSVG), envelope vector (pCPRAEnv) and transfer vector (Thy1-PAD2 pLionII, empty pLionII vector with thy1 promoter only or CMV-YFP pLionII) were mixed in a 10:10:1 ratio. 21 µg of mixed DNA was incubated with 500 µl Opti-MEM (GIBCO) containing 5 µl FuGENE and mixed with HEK-293 cells. Media was changed every 3 days. Old media was collected and filtered with 0.4 µm Super Membrane (PALL). The filtered media was mixed with 100% PEG (Polyethylene Glycol 6000, USB Corporation, Solon, OH) using a 6:4 ratio (v/v) and centrifuged for 20 min at 3500 rpm at 4 °C. The pellet was re-suspended in 300 µl DMEM. 10 µl of Thy1-PAD2 pLionII lentivirus was mixed with 1 µl of CMV-YFP pLionII lentivirus, and the whole mixture was added to HEK-293 cells. Neuronal cells were transfected using lipofectamine TM 2000 (Invitrogen).

The siRNA experiments were performed using siRNA against peptidyl arginine deiminase 2 (PAD2) sequences [Stealth Select RNAi for rat (*Rattus norvegicus*) PAD2 (catalog numbers, Oligo id#, RSS309706, RSS309707, RSS309705). Control siRNA (Invitrogen) unrelated to any known mammalian sequence was also used. The siRNA was transfected using Lipofectamine 2000 (Invitrogen), following the manufacturer's instructions with minor modifications. Briefly, 10^6 cells were collected for each transfection. All siRNA used here were carefully evaluated and were found to down-regulate PAD2 mRNA expression by about 60%. Cells were suspended in DMEM and plated onto 35-mm Petri dishes coated with poly-D-lysine (5mg/ml) (Sigma Chemical Co., St. Louis, MO) after transfection and grown with differentiation medium containing 1% horse serum (ATCC) and 100 ng/ml nerve growth factor (NGF) (Sigma Chemical Co.). The cultures were maintained in a humidified atmosphere of 5% CO₂ at 37 °C. The medium was changed every three days.

Ocular Injections

The mice were anesthetized with intraperitoneal ketamine (50 mg/kg) and xylazine (5 mg/kg). Retrobulbar injections of lidocaine (3 μ L, 4%) were performed with a 23-gauge needle using a supraorbital approach [32]. Intravitreal injections were performed following established methods using a 5 μ L Hamilton syringe with 30-gauge needle connecting to Ultra Micro Pump II (UMPII; World Precision Inc, Sarasota, FL) to deliver 0.5–1 μ L viral construct. Reproducible injections are achieved by the UMPII device. An ointment containing antibiotics and gentamycin was applied to the injection site to prevent infection.

Confocal scanning laser ophthalmoscopy (CSLO) imaging

The mice were anesthetized with intraperitoneal ketamine (50 mg/kg) and xylazine (5 mg/kg), and the eyes were dilated with 2.5% phenylephrine hydrochloride eye drops (Akorn, Lake Forest, IL) before imaging. A small drop of balanced salt solution (BSS, Alcon, Ft Worth, TX) was topically applied on the cornea to prevent dehydration when necessary. The mouse was placed on the platform and wrapped with paper tissue to keep body temperature. Each eye was imaged with a customized Heidelberg Engineering CSLO HRA II (Heidelberg Engineering, Heidelberg, Germany) at the wavelength for green fluorescence (488nm) with a scan angle of 55 degrees and scan rate of 51 frames per second.

Pattern Electroretinogram (PERG) experiments and Flash Electroretinogram (FERG)

ND4(H) mice aged 3–4 months were used in each batch of electrophysiological experiments. Briefly, the mice were anaesthetized using ketamine and xylazine and were gently restrained with the use of a bite bar and a nose holder that allowed unobstructed vision. They were kept at a constant body temperature of 37 °C using a feedback-controlled heating pad with undilated pupils pointing laterally and upward. The active electrode (0.25 mm diameter silver wire configured to a semicircular loop of 2-mm radius) was placed on the corneal surface without limiting the field of view. Reference and ground electrodes were stainless steel needles inserted under the skin of the scalp and tail, respectively [54]. Balanced salt solution (BSS, Alcon, Ft Worth, TX) was topically applied on the cornea to prevent dehydration for the duration of the recording. A visual stimulus of contrast-reversing horizontal bars (field area: 50° × 58°, mean luminance: 50 cd/m², spatial frequency: 0.05 cycle/deg, contrast: 98%, temporal frequency: 1 Hz) was aligned with the projection of the

pupil at the viewing distance of 15 cm. Eyes were not refracted for the viewing distance given that the mouse eye has a large depth of focus because of the pinhole pupil. Retinal signals were amplified (10,000-fold) and bandpass filtered (1–30 Hz). Three consecutive responses to each of 600 contrast reversals were recorded and were superimposed to check for consistency and then averaged (1800 sweeps). The PERG is a light-adapted response. To have a corresponding index of outer retinal function, a light-adapted flash ERG (FERG) was also recorded with undilated pupils in response to strobe flashes of 20 cd/m²/s superimposed on a steady background light of 12 cd/m² and presented within a Ganzfeld bowl. Averaged PERG and FERG consisting of a major positive wave followed by a slower negative wave were automatically analyzed to evaluate the response amplitude. This was defined as sum of the absolute values of maximum and minimum voltages (peak-to-trough amplitude). Statistical analysis was performed by Student's t-test for unpaired data. $P < 0.05$ was considered statistically significant.

Immunoprecipitation (IP)

All procedures were performed under RNase-free conditions for the following experiments. Neuron lysates prepared from rat brain were subjected to immunoprecipitation using different antibodies (Online Resource 1). Briefly, IP was carried out as follows: approximately 67 µg sepharose A beads suspended overnight in 200 µL of 50 mM sodium borate buffer pH 9.0 were incubated with 10 µg antibodies at room temperature for an hour. The beads and antibody were cross-linked by adding 10 µg *dimethyl pimelimidate dihydrochloride* (DMP) three times each with 2 hour incubation at room temperature and then was kept at 4 °C overnight. Antibody-coupled beads were subsequently neutralized with 200 µL of 200 mM ethanolamine and washed with 1 ml of phosphate buffered saline (PBS) twice. The antibody-coupled beads were then incubated with 200 µg of cytosolic lysate for an hour at room temperature. The beads were washed twice with 500 µL of PBS and eluted with two 20 µL volumes of 100 mM glycine pH 3.0. The eluents were combined and divided into 2 equal amounts; one was kept at 4 °C for separation on SDS-PAGE and the other was used for mRNA isolation.

Cloning, purification and in vitro deimination

REF clone (EMM1002-96824126) in plasmid pExpress1 procured from Open Biosystems, (Huntsville, AL) was subcloned in pET19 vector (Novagen, Cat. No. 69677-3). The clone was sequenced and transformed in *E. coli* BL21 cells induced using 0.1 mM IPTG at absorbance values of 0.55–0.8 at 600 nm. Recombinant his-tagged REF was purified using two rounds of Ni-NTA column (Qiagen, Valencia, CA) according to the protocol from the company. In the second round, the purified product from the first round was extensively dialyzed using a 3500 MWCO membrane (Sigma Chemical Co.) in PBS and re-purified on a Ni-NTA column using 100 mM imidazole for elution. The final purified product was subjected to dialysis.

Briefly, PAD2 (Sigma-Aldrich, St. Louis, MO) was incubated under deiminating conditions with dialyzed REF. The recombinant REF (100 µg) was deiminated in vitro using 6 µg PAD2, re-purified using a Ni-NTA column, dialyzed, and then quantified using Bradford's method.

IP experiments for the identification of translation complexes were performed using 5 µg of recombinant, his-tagged, deiminated and non-deiminated REF. Each batch was incubated with 1000 µg of cytosolic cell fraction extract for 1 hour, incubated with approximately 50 µl of Ni-NTA beads, and loaded onto a mini column. The column was then washed with 50 volumes of binding buffer (PBS, 5 mM imidazole) and the bound his-tagged protein was eluted using 100 mM and 250 mM imidazole. Similar IPs were also performed with cultured RGC utilizing 5 µg of REF (deiminated and control) and 100 µg of protein extracts. Eluted proteins were either dialyzed to remove imidazole or acetone precipitated [55] and subjected to further analyses.

For protein identification, concentrated protein was digested *in-situ* with sequencing grade trypsin (Promega Biosciences Inc, CA). Peptides were loaded onto 3 cm YMC ODS-A spherical 5–15 µm (YMC, Milford, MA) pre-columns packed in-house in 360×100 µm fused silica and washed for 5 min to desalt prior to switching inline with the analytical column (7 cm YMC-ODS AQ spherical 5 µm particles packed in-house in 360×100 µm fused silica). Peptides were eluted along a 20 min gradient of 1–80% acetonitrile in 0.1% formic acid 0.1 M acetic acid into a Thermo Q-Exactive™ orbitrap mass spectrometer fitted with a nanospray ionization source (Easy nLC 1000, ThermoFisher Scientific). Spectra were collected in data-dependent mode with dynamic exclusion, selecting the top five most abundant ions for CID fragmentation. Peak lists were generated using Sequest (ThermoElectron, San Jose, CA) and submitted to a clustered version of the SequestHT search engine. Spectra were searched against SwissProt Fasta database (EBI, Cambridge, UK) with no more than two missed tryptic cleavages. Precursor ion tolerance was set to 10 ppm, 2 Da and fragment tolerance to 0.6 Da. Carbamidomethylation of cysteine was fixed for analysis; variable modifications of oxidized methionine and citrullinated arginine were permitted during the search. Sequest result files were loaded into Scaffold (Proteome Software, Portland, OR) for analysis through the PeptideProphet and ProteinProphet algorithms followed by manual validation of all proteins identified with at least two peptides and at a protein confidence of greater than 90%. For determination of deiminated/ citrullinated peptides, the protein mixtures were subjected to chymotrypsin digestion and tandem mass spectrometry in an Orbitrap device (ThermoFinnigan, San Jose, CA).

RNA extraction and reverse transcription PCR

The eluents from IP as described above were collected, and RNA species together with REF or ANP32a were isolated using the miniRNA extraction kit (Stratagene Inc., La Jolla, CA) as per manufacturer's recommended protocol. Total RNA was dissolved in DEPC-treated distilled water and converted to cDNA with the oligo dT (12–18) (Invitrogen Inc., Carlsbad, CA) following two-step reactions provided by the company. For detection of mRNA species, RT-PCR of IP product-derived mRNA was carried out with primers for different mRNAs (Online Resource 2) under a mild PCR condition according to manufacturer's instruction (Advantage cDNA PCR kit; Clontech Inc., Mountain View, CA) and separated on a 2.0% agarose gel made with TBE buffer.

Lectin staining and separations

Primary cortical neurons (10^6) were plated in the 10 cm plate for 6–7 days. The plate was washed 3X with PBS. 10 mL PBS solution containing 2 $\mu\text{g}/\text{mL}$ of lectin was added in the plates, which were maintained in a humidified atmosphere of 5% CO_2 at 37 °C for 4 hours. Excess solution was then removed by pipet and discarded. The plate was again washed 3X with PBS. 40 μL of magnetic Streptavidin beads (Thermo Fisher Scientific, Grand Island, NY) in 5 mL PBS were added to each flask and mixed on a shaker for 1 hour. Excess solution was then removed. Using a plastic dish scraper, the cells were sheared and separated from the flask surface by force. The resulting liquid was transferred to a micropipette tube. A magnetic stand was used to separate beads with attached cellular particulate from the remaining solution. The supernatant was transferred to a separate container, and Lectin 3 was added to make the final concentration 2 $\mu\text{g}/\text{mL}$. The remaining particulate was then washed once with 0.5 mL of 0.1% Tween-20 in PBS to remove any remaining buffer. For elution of particulate bound to the Streptavidin beads, the beads were then washed with two aliquots of 50 μL elution buffer (0.1 M glycine at pH 2.0 for 5 minutes at 65 °C) followed by magnetic separation on each aliquot. Tris buffer pH 8.0 was added to 10% total volume for neutralization. The separation of the supernatant with Lectin 3 was repeated, and the elution was collected as above.

Neuron growth in axon isolation chamber and ex-vivo/in vitro blocker

The slides were coated with 5 mg/mL Poly-D-Lysine (Sigma-Aldrich, St. Louis, MO) overnight and washed with distilled water. The axon isolation chamber (AXIS) (Millipore, Temecula, CA) was attached to the slides as per the manufacturer's instructions. Briefly, neuronal cells (4×10^6) were loaded into the channel area, and media was added in the wells (Online Resource 3). In order to over-express the PAD2, we add 10 μL of Thy1-PAD2 pLionII lentivirus or the empty virus (control) to the channel areas two days after plating the neurons. The chambers were maintained in a humidified atmosphere of 5% CO_2 at 37 °C for 6 days. Growth media in chambers C and D (Online Resource 3) was replaced by media containing lipid (1 nM) and the blockers lidocaine (10 mM, Sigma-Aldrich, St. Louis, MO) or vincristine (50 nM, Sigma-Aldrich). 10 min after adding the blockers, neuronal transport was analyzed using time-lapse microscopy (Carl Zeiss, Oberkochen, Germany). Images were acquired every 15 min for 3 hours.

Lipid extraction and mass spec identification

IP samples were subjected to the Bligh and Dyer method [56] of lipid extraction with suitable modifications using butylated hydroxytoluene (Sigma-Aldrich, St. Louis, MO) and argon gas to prevent oxidation as per established procedures [57–59]. Briefly, the organic phase containing the extracted lipids was dried, flushed with Argon gas, and stored at -80°C until mass spectrometric analysis. The corresponding aqueous phase was used for protein quantification using the Bradford protein assay as per established procedures [57].

Dried lipids were separated on an Ascentis Express column (C_{18} , 2.1×150 mm, 2.7 μm , 90 Å pore size, Sigma-Aldrich, St. Louis, MO) connected to an Easy nLC 1000 Liquid Chromatograph instrument (ThermoFisher, San Jose, CA), which fed into a Q-Exactive orbitrap mass spectrometer (ThermoFisher, San Jose, CA). A binary solvent system (mobile

phase A consisted of acetonitrile: water (60:40) (v/v), 10 mM ammonium formate, and 0.1% formic acid; mobile phase B consisted of isopropanol: acetonitrile (90:10) (v/v), 10 mM ammonium formate, and 0.1% formic acid) was used in a 30 min gradient as per established methods [60,61]. The following gradient conditions with increasing eluent B were used: 0–1.5 min increase to 32% B; 1.5–4 min increase to 45% B; 4–5 min increase to 52% B; 5–8 min increase to 58% B; 8–11 min increase to 66% B; 11–14 min increase to 70% B; 14–18 min increase to 75% B; 18–21 min increase to 97% B; 21–25 min held at 97% B; 25–25.1 min decrease to 32% B; and 25.1–30 min held at 32% B. Dried lipid samples were re-suspended in 100 μ L acetonitrile: isopropanol (50:50) (v/v), of which 2 μ L were injected. Flow rate was set to 400 μ L/min. The Q-Exactive mass spectrometer equipped with a HESI-I probe was set for positive mode acquisition. The method for lipid analysis was based on previously optimized and experimentally determined parameters [62]. Mass resolution was set to 70,000 for full-MS with Top-10 MS² at resolution 17,500 (FWHM at m/z 200 for both). Normalized collision energy was set to 35. A dynamic exclusion of eight seconds was found to resolve partially separated isomers. An isolation window of 1.2 Da was found to be the optimal balance between a good ion transmission and false positive IDs by the LipidSearch 4.0 (Thermo Fisher, San Jose, CA). An injection time of 75 ms was found as optimal. An exclusion list was determined by injecting blank resuspension buffer under the same conditions and was added to the method above. Spray voltage was set to 3000 V, the ion transfer tube was held at 285 °C, S-Lens was set to 45%, and sheath gas and auxiliary gas were held at 60 and 20 arbitrary units, respectively. Sweep gas was at 1 arbitrary unit. The automatic gain control (AGC) of full-MS was 1e6, and for MS² at 1e5. Mass range was 150–2000 m/z, with a first fixed mass at 75 Da [62].

Virus construct

The Full length mRNA sequences of Synaptosomal-associated protein 25 (Snap25) (NM_011428.3), Syntaxin binding protein 3 (Stxbp3) (NM_011504.1) and Sphingosine kinase 2 transcript variant 1 (Sphk2) (NM_203280.3) were obtained from NCBI as referred. The cDNAs generated from the total mouse brain mRNAs by reverse transcription using oligo dT.

The 5' untranslated region (UTR) region is defined by full sequence mRNAs upstream of start codon (AUG) and 3' UTR is defined by the downstream of the stop codon (UAA or UAG). Different set of primers including restriction sites for BamHI (forward) and NdeI (reverse) were prepared to amplify the 5' UTR of Sphk2 (464bp); SNAP25 (225bp). mCherry was cloned from pmCherry vector using primers including restriction sites for NdeI(forward) and NotI(reverse). For Stxbp3, the 5' UTR sequence was included in the primers. The 5' UTR and mCherry were cloned together by PCR using the primers including restriction sites for BamHI (forward) and NotI (reverse). Another set of primers including restriction sites for NotI (forward) and KpnI (reverse) are designed to clone 3' UTR region of Sphk2 (1286 bp); SNAP25 (1316 bp); Stxbp3 (617 bp). A summary of all the primers are listed in Online Resource 2. PCR products were subjected to verification by agarose gel electrophoresis. The PCR bands were excised and extracted from the agarose gel using a QIAGEN Gel Extraction Kit (Qiagen, Valencia, CA). The concentration of gel purified DNA was determined using a UV/visible spectrophotometer. The inserts and vector

pWPXL (addgene) were simultaneously digested using restriction enzymes which would excise the GFP region on the vector. The digested inserts, and vector were again subjected to gel electrophoresis, and were extracted using the Gel Extraction Kit. The vector was dephosphorylated with calf intestinal alkaline phosphatase (CIP). The digested vector and insert DNA were ligated in a ratio of 1:3 by incubating with T4 ligase at 37°C for 2 hours. The ligated constructs were used for transformation of DH5 α competent E. coli cells. The colonies of transformants were picked and isolated DNA was subjected to confirmation for presence of insert by double digestion of the plasmid and also by the expression of mCherry. The construct was further confirmed by DNA sequencing.

Virus production and transfection

pWPXL constructs were transfected separately to 293 Human Embryonic Kidney (HEK) cells using FuGENE 6 Transfection Reagent (Roche - Cat. No. 11 815 091 001). Briefly, structural vector (psPAX2), envelope vector (pMD2.G) and transfer vector (pWPXL-stxbp3/sphk2/snap25) were mixed with 10:10:1 ratio. 21 μ g of mixed DNA was incubated with 500 μ l Opti-MEM (GIBCO) containing 5 μ l FuGENE and mixed with 293 HEK cells. Media was changed every 3 days. Old media was collected and filtrated with 0.4 μ m Super Membrane (PALL). The viral construct containing REF-GFP or ANP32a-GFP were purchased from Genecopeia (EX-Mm34605-lv122; EX-Mm01200-Lv103). The virus was produced in HEK293 cell following the procedures provided in the Lenti-PacTM Lentiviral Packaging Systems kit (HPK-LvTR-20).

The 2 days primary cortical neurons were co-infected with REF-GFP or ANP32a-GFP and one of the virus containing the construct (Snap25, Stxbp3 or Sphk2) (v:v 1:1) by replacing 1/3 of the medium with the media containing virus. The neurons which without overexpression of REF-GFP or ANP32a-GFP were using as controls. The expression of the proteins was confirmed after 24–48 hours. Imaging was performed after 48 hours.

Microscopy

Fluorescence recovery after photobleaching (FRAP) was done using Leica SP8 (Mannheim, Germany) utilizing a 63x Plan Apo (1.4 NA). First an appropriate field was localized that expressed both endogenous markers. Next, the nuclear region of interest was selected for the cell. One pre photobleach image acquired using the appropriate laser, and filter setting. GFP detection was accomplished using a 488 nm excitation laser, and a 490–532 nm emission. mCherry was detected using a 561 laser, and a 577–680 nm emission. Photobleaching, then commenced with a 561 nm laser for 60 S. Finally, recovery images were acquired for at a rate of one image per minute for a total duration of ten minutes.

Quantification, bioinformatic identification, and statistical analysis

Chromatograms were automatically processed using LipidSearch 4.0, with a precursor mass tolerance of 3 ppm, a product mass tolerance of 7 ppm, and an m-Score threshold of 3 as per established methods [62]. An internal standard was used for ratiometric quantification in a two-step process [63,64]. Briefly, in the first step, the most abundant lipids in the class were quantified using internal standards, and the measurements from the first step were used for quantification of low-abundance species in the second step [64,65,57]. The internal

standards were procured from and made by Avanti Polar Lipids (Alabaster, AL) in conjunction with LipidMaps (www.lipidmaps.org) specifically for LC-MS quantification use. The following were used in ratiometric quantification of phospholipids: 17:0-20:4 PI (catalog no. LM-1502) for PI; 17:0-20:4 PS (catalog no. LM-1302) for PS; 17:0-20:4 PE (catalog no. LM-1102) for PE; and 17:0-20:4 PC (catalog no. LM-1002) for PC. The lipid amount was normalized to the protein amount determined from the corresponding aqueous phase as described above. Lipids were also subjected to normalization as a percent of total lipids. Comparison of lipid profiles between tissues or fluids were performed using in-house written Excel macros as described previously for other studies [57,59,65,63]. Reported lipids were found statistically significant using Student's t-test ($p < 0.05$). For lipids that were unique, a value zero was used for the groups devoid of the specific lipid. The number of samples was then assumed to be equivalent to the frequency of occurrence of the unique group. The select common lipid species had statistically significant differences between two groups by ANOVA. Scheffe's post hoc test showed that select lipids species in control group were statistically different from the comparison group ($p < 0.05$).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was partially supported by an unrestricted grant from Research to Prevent Blindness to the University of Miami, DoD grant W81XWH-16-1-0715, and NIH grants P30 EY014801, EY014957, EY019077, NS034773, U01EY027257. We thank A. Trzeciacka for providing part of the neurons. We thank G. Gaidosh for assistance with microscopy. We thank Dr. K. Park for their critical comments on the manuscript.

References

1. Martin KC, Ephrussi A. 2009; mRNA localization: gene expression in the spatial dimension. *Cell*. 136(4):719–730. DOI: 10.1016/j.cell.2009.01.044 [PubMed: 19239891]
2. Kim S, Martin KC. 2015; Neuron-wide RNA transport combines with netrin-mediated local translation to spatially regulate the synaptic proteome. *eLife*. :4.doi: 10.7554/eLife.04158
3. Kalinski AL, Sachdeva R, Gomes C, Lee SJ, Shah Z, Houle JD, Twiss JL. 2015; mRNAs and Protein Synthetic Machinery Localize into Regenerating Spinal Cord Axons When They Are Provided a Substrate That Supports Growth. *J Neurosci*. 35(28):10357–10370. DOI: 10.1523/JNEUROSCI.1249-15.2015 [PubMed: 26180210]
4. Park KK, Liu K, Hu Y, Smith PD, Wang C, Cai B, Xu B, Connolly L, Kramvis I, Sahin M, He Z. 2008; Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. *Science*. 322(5903):963–966. DOI: 10.1126/science.1161566 [PubMed: 18988856]
5. Sun F, Park KK, Belin S, Wang D, Lu T, Chen G, Zhang K, Yeung C, Feng G, Yankner BA, He Z. 2011; Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. *Nature*. 480(7377):372–375. DOI: 10.1038/nature10594 [PubMed: 22056987]
6. Steward O, Levy WB. 1982; Preferential localization of polyribosomes under the base of dendritic spines in granule cells of the dentate gyrus. *J Neurosci*. 2(3):284–291. [PubMed: 7062109]
7. Kar AN, MacGibeny MA, Gervasi NM, Gioio AE, Kaplan BB. 2013; Intra-axonal synthesis of eukaryotic translation initiation factors regulates local protein synthesis and axon growth in rat sympathetic neurons. *J Neurosci*. 33(17):7165–7174. DOI: 10.1523/JNEUROSCI.2040-12.2013 [PubMed: 23616526]
8. Friede RL, Bischhausen R. 1980; The fine structure of stumps of transected nerve fibers in subserial sections. *Journal of the neurological sciences*. 44(2–3):181–203. [PubMed: 7188775]

9. Han SB, Kim H, Skuba A, Tessler A, Ferguson T, Son YJ. 2012; Sensory Axon Regeneration: A Review from an in vivo Imaging Perspective. *Experimental neurobiology*. 21(3):83–93. DOI: 10.5607/en.2012.21.3.83 [PubMed: 23055786]
10. Liuzzi FJ, Tedeschi B. 1991; Peripheral nerve regeneration. *Neurosurgery clinics of North America*. 2(1):31–42. [PubMed: 1821734]
11. Windle WF. 1980; Inhibition of regeneration of severed axons in the spinal cord. *Experimental neurology*. 69(1):209–211. [PubMed: 7389848]
12. Erturk A, Hellal F, Enes J, Bradke F. 2007; Disorganized microtubules underlie the formation of retraction bulbs and the failure of axonal regeneration. *J Neurosci*. 27(34):9169–9180. DOI: 10.1523/JNEUROSCI.0612-07.2007 [PubMed: 17715353]
13. Verma P, Chierzi S, Codd AM, Campbell DS, Meyer RL, Holt CE, Fawcett JW. 2005; Axonal protein synthesis and degradation are necessary for efficient growth cone regeneration. *J Neurosci*. 25(2):331–342. DOI: 10.1523/JNEUROSCI.3073-04.2005 [PubMed: 15647476]
14. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. 2003; PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. *Bioessays*. 25(11):1106–1118. DOI: 10.1002/bies.10357 [PubMed: 14579251]
15. Bhattacharya SK, Crabb JS, Bonilha VL, Gu X, Takahara H, Crabb JW. 2006; Proteomics implicates peptidyl arginine deiminase 2 and optic nerve citrullination in glaucoma pathogenesis. *Invest Ophthalmol Vis Sci*. 47(6):2508–2514. [PubMed: 16723463]
16. Enriquez-Algeciras M, Ding D, Chou TH, Wang J, Padgett KR, Porciatti V, Bhattacharya SK. 2011 Evaluation of a transgenic mice model of multiple sclerosis with non invasive methods. *Invest Ophthalmol Vis Sci*.
17. Bhattacharya SK. 2009; Retinal deimination in aging and disease. *IUBMB Life*. 61(5):504–509. [PubMed: 19391158]
18. Ding D, Enriquez-Algeciras M, Dave KR, Perez-Pinzon M, Bhattacharya SK. 2012; The role of deimination in ATP5b mRNA transport in a transgenic mouse model of multiple sclerosis. *EMBO Rep*. 13(3):230–236. [PubMed: 22261716]
19. Moscarello MA, Wood DD, Ackerley C, Boulias C. 1994; Myelin in multiple sclerosis is developmentally immature. *J Clin Invest*. 94(1):146–154. [PubMed: 7518827]
20. Bhattacharya SK, Sinicrope B, Rayborn ME, Hollyfield JG, Bonilha VL. 2008; Age-related reduction in retinal deimination levels in the F344BN rat. *Aging Cell*. 7(3):441–444. DOI: 10.1111/j.1474-9726.2008.00376.x [PubMed: 18248664]
21. Enriquez-Algeciras M, Ding D, Mastronardi FG, Marc RE, Porciatti V, Bhattacharya SK. 2013; Deimination restores inner retinal visual function in murine demyelinating disease. *J Clin Invest*. 123(2):646–656. [PubMed: 23281397]
22. Udin SB. 2005; Chronic melatonin and binocular plasticity in *Xenopus* frogs. General and comparative endocrinology. 142(3):274–279. DOI: 10.1016/j.ygcen.2005.01.014 [PubMed: 15935153]
23. Udin SB, Fisher MD. 1985; The development of the nucleus isthmi in *Xenopus laevis*. I. Cell genesis and the formation of connections with the tectum. *The Journal of comparative neurology*. 232(1):25–35. DOI: 10.1002/cne.902320103 [PubMed: 3973081]
24. Sim ME, Lyoo IK, Streeter CC, Covell J, Sarid-Segal O, Ciraulo DA, Kim MJ, Kaufman MJ, Yurgelun-Todd DA, Renshaw PF. 2007; Cerebellar gray matter volume correlates with duration of cocaine use in cocaine-dependent subjects. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*. 32(10):2229–2237. DOI: 10.1038/sj.npp.1301346 [PubMed: 17299505]
25. Herold A, Suyama M, Rodrigues JP, Braun IC, Kutay U, Carmo-Fonseca M, Bork P, Izaurralde E. 2000; TAP (NXF1) belongs to a multigene family of putative RNA export factors with a conserved modular architecture. *Mol Cell Biol*. 20(23):8996–9008. [PubMed: 11073998]
26. Khan MZ, Vaidya A, Meucci O. 2011; CXCL12-mediated regulation of ANP32A/Lanp, a component of the inhibitor of histone acetyl transferase (INHAT) complex, in cortical neurons. *Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology*. 6(1):163–170. DOI: 10.1007/s11481-010-9228-5 [PubMed: 20617464]

27. Cohen MS, Bas Orth C, Kim HJ, Jeon NL, Jaffrey SR. 2011; Neurotrophin-mediated dendrite-to-nucleus signaling revealed by microfluidic compartmentalization of dendrites. *Proc Natl Acad Sci U S A*. 108(27):11246–11251. DOI: 10.1073/pnas.1012401108 [PubMed: 21690335]
28. Corral-Debrinski M. 2007; mRNA specific subcellular localization represents a crucial step for fine-tuning of gene expression in mammalian cells. *Biochim Biophys Acta*. 1773(4):473–475. [PubMed: 17292980]
29. Shigeoka T, Jung H, Jung J, Turner-Bridger B, Ohk J, Lin JQ, Amieux PS, Holt CE. 2016; Dynamic Axonal Translation in Developing and Mature Visual Circuits. *Cell*. 166(1):181–192. DOI: 10.1016/j.cell.2016.05.029 [PubMed: 27321671]
30. Kanai A, Hiruma H, Katakura T, Sase S, Kawakami T, Hoka S. 2001; Low-concentration lidocaine rapidly inhibits axonal transport in cultured mouse dorsal root ganglion neurons. *Anesthesiology*. 95(3):675–680. [PubMed: 11575541]
31. LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. 2013; Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. *Neurotoxicology*. 37:231–239. DOI: 10.1016/j.neuro.2013.05.008 [PubMed: 23711742]
32. Chou TH, Park KK, Luo X, Porciatti V. 2013; Retrograde signaling in the optic nerve is necessary for electrical responsiveness of retinal ganglion cells. *Invest Ophthalmol Vis Sci*. 54(2):1236–1243. DOI: 10.1167/iov.12-11188 [PubMed: 23307964]
33. Young P, Qiu L, Wang D, Zhao S, Gross J, Feng G. 2008; Single-neuron labeling with inducible Cre-mediated knockout in transgenic mice. *Nature neuroscience*. 11(6):721–728. DOI: 10.1038/nn.2118 [PubMed: 18454144]
34. Mastronardi FG, Ackerley CA, Arsenault L, Roots BI, Moscarello MA. 1993; Demyelination in a transgenic mouse: a model for multiple sclerosis. *J Neurosci Res*. 36(3):315–324. DOI: 10.1002/jnr.490360309 [PubMed: 7505836]
35. Johnson RS, Roder JC, Riordan JR. 1995; Over-expression of the DM-20 myelin proteolipid causes central nervous system demyelination in transgenic mice. *J Neurochem*. 64(3):967–976. [PubMed: 7532214]
36. Ahn S, Joyner AL. 2005; In vivo analysis of quiescent adult neural stem cells responding to Sonic hedgehog. *Nature*. 437(7060):894–897. [PubMed: 16208373]
37. Song J, Zhong C, Bonaguidi MA, Sun GJ, Hsu D, Gu Y, Meletis K, Huang ZJ, Ge S, Enikolopov G, Deisseroth K, Luscher B, Christian KM, Ming GL, Song H. 2012; Neuronal circuitry mechanism regulating adult quiescent neural stem-cell fate decision. *Nature*. 489(7414):150–154. [PubMed: 22842902]
38. Bassell GJ, Kelic S. 2004; Binding proteins for mRNA localization and local translation, and their dysfunction in genetic neurological disease. *Current opinion in neurobiology*. 14(5):574–581. DOI: 10.1016/j.conb.2004.08.010 [PubMed: 15464890]
39. Bassell GJ, Zhang H, Byrd AL, Femino AM, Singer RH, Taneja KL, Lifshitz LM, Herman IM, Kosik KS. 1998; Sorting of beta-actin mRNA and protein to neurites and growth cones in culture. *J Neurosci*. 18(1):251–265. [PubMed: 9412505]
40. Besse F, Ephrussi A. 2008; Translational control of localized mRNAs: restricting protein synthesis in space and time. *Nat Rev Mol Cell Biol*. 9(12):971–980. DOI: 10.1038/nrm2548 [PubMed: 19023284]
41. Doron-Mandel E, Fainzilber M, Terenzio M. 2015; Growth control mechanisms in neuronal regeneration. *FEBS Lett*. 589(14):1669–1677. DOI: 10.1016/j.febslet.2015.04.046 [PubMed: 25937120]
42. Liu K, Tedeschi A, Park KK, He Z. 2011; Neuronal intrinsic mechanisms of axon regeneration. *Annu Rev Neurosci*. 34:131–152. [PubMed: 21438684]
43. Yoo S, van Niekirk EA, Merianda TT, Twiss JL. 2010; Dynamics of axonal mRNA transport and implications for peripheral nerve regeneration. *Experimental neurology*. 223(1):19–27. DOI: 10.1016/j.expneurol.2009.08.011 [PubMed: 19699200]
44. Benowitz LI, Yin Y. 2007; Combinatorial treatments for promoting axon regeneration in the CNS: strategies for overcoming inhibitory signals and activating neurons' intrinsic growth state. *Dev Neurobiol*. 67(9):1148–1165. DOI: 10.1002/dneu.20515 [PubMed: 17514713]

45. Encalada SE, Goldstein LS. 2014; Biophysical Challenges to Axonal Transport: Motor-Cargo Deficiencies and Neurodegeneration. Annual review of biophysics. doi: 10.1146/annurev-biophys-051013-022746
46. Crish SD, Sappington RM, Inman DM, Horner PJ, Calkins DJ. 2010; Distal axonopathy with structural persistence in glaucomatous neurodegeneration. Proc Natl Acad Sci U S A. 107(11): 5196–5201. DOI: 10.1073/pnas.0913141107 [PubMed: 20194762]
47. LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, Brady ST. 2009; The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res. 87(2):440–451. DOI: 10.1002/jnr.21850 [PubMed: 18798283]
48. Koch JC, Bitow F, Haack J, d'Hedouville Z, Zhang JN, Tonges L, Michel U, Oliveira LM, Jovin TM, Liman J, Tatenhorst L, Bahr M, Lingor P. 2015; Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons. Cell death & disease. 6:e1811.doi: 10.1038/cddis.2015.169 [PubMed: 26158517]
49. Roy S, Zhang B, Lee VM, Trojanowski JQ. 2005; Axonal transport defects: a common theme in neurodegenerative diseases. Acta neuropathologica. 109(1):5–13. DOI: 10.1007/s00401-004-0952-x [PubMed: 15645263]
50. Winans AM, Collins SR, Meyer T. 2016; Waves of actin and microtubule polymerization drive microtubule-based transport and neurite growth before single axon formation. eLife. :5.doi: 10.7554/eLife.12387
51. JNPF. A Normal Table of *Xenopus laevis* (Daudin). 2. North-Holland Publishing Company; North Holland, Amsterdam: 1967.
52. Kim EJ, Raval AP, Perez-Pinzon MA. 2008; Preconditioning mediated by sublethal oxygen-glucose deprivation-induced cyclooxygenase-2 expression via the signal transducers and activators of transcription 3 phosphorylation. J Cereb Blood Flow Metab. 28(7):1329–1340. DOI: 10.1038/jcbfm.2008.26 [PubMed: 18398416]
53. Thompson JW, Dave KR, Saul I, Narayanan SV, Perez-Pinzon MA. 2013; Epsilon PKC increases brain mitochondrial SIRT1 protein levels via heat shock protein 90 following ischemic preconditioning in rats. PLoS One. 8(9):e75753.doi: 10.1371/journal.pone.0075753 [PubMed: 24058702]
54. Porciatti V. 2007; The mouse pattern electroretinogram. Doc Ophthalmol. 115(3):145–153. DOI: 10.1007/s10633-007-9059-8 [PubMed: 17522779]
55. Patel N, Solanki E, Picciani R, Cavett V, Caldwell-Busby JA, Bhattacharya SK. 2008; Strategies to recover proteins from ocular tissues for proteomics. Proteomics. 8(5):1055–1070. [PubMed: 18324731]
56. Bligh EG, Dyer WJ. 1959; A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 37(8):911–917. [PubMed: 13671378]
57. Aribindi K, Guerra Y, Lee RK, Bhattacharya SK. 2013; Comparative phospholipid profiles of control and glaucomatous human trabecular meshwork. Invest Ophthalmol Vis Sci. 54(4):3037–3044. [PubMed: 23557733]
58. Crane AM, Hua HU, Coggin AD, Gugiu BG, Lam BL, Bhattacharya SK. 2012; Mass spectrometric analyses of phosphatidylcholines in alkali-exposed corneal tissue. Invest Ophthalmol Vis Sci. 53(11):7122–7130. [PubMed: 22956606]
59. Aribindi K, Guerra Y, del Piqueras MC, Banta JT, Lee RK, Bhattacharya SK. 2013; Cholesterol and glycosphingolipids of human trabecular meshwork and aqueous humor: comparative profiles from control and glaucomatous donors. Curr Eye Res. 38(10):1017–1026. [PubMed: 23790057]
60. Bird SS, Marur VR, Sniatynski MJ, Greenberg HK, Kristal BS. 2011; Lipidomics profiling by high-resolution LC-MS and high-energy collisional dissociation fragmentation: focus on characterization of mitochondrial cardiolipins and monolysocardiolipins. Analytical chemistry. 83(3):940–949. DOI: 10.1021/ac102598u [PubMed: 21192696]
61. Hu C, van Dommelen J, van der Heijden R, Spijksma G, Reijmers TH, Wang M, Slee E, Lu X, Xu G, van der Greef J, Hankemeier T. 2008; RPLC-ion-trap-FTMS method for lipid profiling of plasma: method validation and application to p53 mutant mouse model. Journal of proteome research. 7(11):4982–4991. DOI: 10.1021/pr800373m [PubMed: 18841877]

62. Josef Ruzicka, KJM; Peake, David. Data Acquisition Parameters Optimization of Quadrupole Orbitrap for Global Lipidomics on LC-MS/MS time frame. Paper presented at the American Society for Mass Spectrometry; Baltimore, Maryland. 2014.
63. Edwards G, Aribindi K, Guerra Y, Lee RK, Bhattacharya SK. 2014; Phospholipid profiles of control and glaucomatous human aqueous humor. *Biochimie*. 101:232–247. DOI: 10.1016/j.biochi.2014.01.020 [PubMed: 24561385]
64. Yang K, Zhao Z, Gross RW, Han X. 2009; Systematic analysis of choline-containing phospholipids using multi-dimensional mass spectrometry-based shotgun lipidomics. *J Chromatogr B Analyt Technol Biomed Life Sci*. 877(26):2924–2936.
65. Edwards G, Aribindi K, Guerra Y, Bhattacharya SK. 2014; Sphingolipids and ceramides of mouse aqueous humor: Comparative profiles from normotensive and hypertensive DBA/2J mice. *Biochimie*. doi: 10.1016/j.biochi.2014.06.019

Fig. 1.

Deimination level is associated with growth status of neuron. **a** Representative normal and eye-rotated frog tectum, detected with antibody against deimination as indicated. Tracer indicates isthomo-tectal projection after eye rotation concomitant with elevated deimination. Bar=50 μ m. **b** Semiquantitative fluorescent signal from comparative area quantified by Image J ($n=6$; $*p < 0.005$). **c** Representative Western blot analysis of deimination and PAD2 level in frog tectum (control and rotated as indicated). Densitometric quantification from similar blots ($n=6$; $*p < 0.005$). **d** Representative saline (control) and cocaine treated (chronic) mouse cerebellum, detected with anti-PAD2 and SMI312 antibody as indicated. Bar=50 μ m. **e** Fluorescent signal from comparative area quantified by Image J ($n=3$, $*p < 0.005$). **f** Western blot analysis of SNAP-25 and PAD2 level in mouse cerebellum (control and chronic cocaine treatment as indicated). Densitometric quantification from similar blots ($n=6$; $*p < 0.005$). **g** Western blot analysis of PAD2, REF, ANP32a in 0, 4, 6 days neurons, GAPDH is used as control. **h** Detection of PAD2 expression in postnatal day 1 and 7 (P1, P7), 1 month, 3 month, 5 month old mouse optic nerve

Fig. 2.

Deimination is associated with neuronal growth and polarity. **a–b** PAD2 expression by immunocytochemistry in two neuronal cell lines, PC12 and Neuro 2A. Bar=20 μ m. **a** Detection of PAD2 and ANP32a in PC12 cells and primary cortical neurons without (control) or with Nerve Growth Factor (NGF). **b** Detection of PAD2 and ANP32a expression in Neuro 2A cells and primary cortical neurons without (control) or with a treatment of 20 aa inhibitory peptide of MBP (MBP P). **c** Western blot of PAD2, REF in PC12 and Neuro 2A cell lines as indicated. Densitometric quantification of deimination level from similar blots (n=6; *p 0.005). **d** Detection of ANP32a location and deimination (green) in cortical neurons without (control) and with ANP32a (red) siRNA mediated PAD2 inhibition

Fig. 3.

Proteins and their interactors under regulation of deimination. **a** Western blot of REF, ANP32a, Dynactin (DCTN), KIF21b in the immunoprecipitation (IP) products as indicated using PAD2 antibody in primary cortex cultures. **b** Western blot of REF, KIF21b and DCTN in the IPs of different motor proteins. **c** Pull down assay with mass spectrometry using non-deiminated REF (D-) and deiminated REF (D+). **d** Comparison of average neurites length for control and PAD2 over expression as indicated (n=20 neurons per group; *p 0.005). **e** Representative Western blot indicates post-transfection PAD2 expression. **f** Detection of ANP32a, PAD2, SNAP-25 and Rab3 in primary cortical neuron with over expression of PAD2 and control (empty viral vector). Bar=20μm. Antibodies used in this study are listed in Online Resource 1

Fig. 4.

Deimination regulates cargo distribution in different compartments in neurons. **a**

Localization of Lectin2 (*Maclura pomifera* lectin) and Lectin3 (*Canavalia ensiformis* lectin) in primary cortical neurons (IHC) and Neuro 2A cells as indicated. Bar=20μm. Western blot of fractions (illustrated with fraction-nomenclature in the schematic shown in the right) using markers for cell body and neurites from different eluents, 2E, eluent after Lectin 2 binding; 2S, flow through after Lectin 2 binding; 3S, flow through after Lectin 3; TCE, total cell extract. **b** Western blot of selected proteins in different neuron compartmental fractions as indicated. **c** Quantification of distribution of selected proteins after induction (+) or inhibition (–) of PAD2 expression and controls (C) based on Western blot analysis (n=10) and densitometry. Mean ± standard deviation. Neurite and cell body are color coded as indicated. **d** Selected mRNAs in cDNA derived from two independent immunoprecipitation (IP) products (using antibodies to REF and ANP32 as indicated), N, Neurites, CB, Cell body. **e** Distribution of select mRNAs in different cellular compartments of neurons after viral vector mediated up (+ PAD2) or down regulation of PAD2 (–PAD2). The Primers used in this study are listed in Online Resource 2

Fig. 5.

REF regulated mRNA transport and translation. The recovery of fluorescent signals after bleaching were monitored from 0s to 4 min with 1 minute interval between control **a** and the cells with overexpression of REF **b**. The red signal is from a construct that expresses mCherry protein flanked with 5' and 3' untranslated region (UTR) of STX3. The green signal is from REF fused with GFP. The REF binding (with UTR regions of STX3) and translation of this construct results in mCherry expression. Arrows indicate co-localization

Fig. 6.

Deimination and neuronal transport probed using fluorescent lipid tracers. **a** Fluorescent lipid transport in neurons. Transport of phosphatidylcholine (PC), phosphatidylserine (PS) are as indicated. **b** Fluorescent image of PHAST gel fractionated neuronal extract cross-linked with lipid (PC), the proteins from the bands were extracted and follows by Mass Spectrometry. The control refers to a PS lipid cross-linked neuronal extract proteins. **c** Scheme for lipids identification. Anti-motor IP products are subjected to lipid extraction and mass spectrometry. **d** Quantification of fluorescent lipid signal. Blue, red and grey lines represents control, +vincristine only and +PAD2+vincristine respectively. Each point represents leading edge of the signal at 15 min intervals, data is presented as mean $\pm$ SEM. Thus +PAD2+Vincristine shows enhanced transport of signal compared to +Vincristine only. **e** A specific lipid was loaded on one side of a neuron using microfluidic chamber and its transport in the presence of lidocaine. An identical set up had a PAD2 overexpressing neuron. Snapshots of transport between 0–75 minutes have been shown as indicated. The movement of granules (indicated by arrows) is significantly increased due to PAD2

expression even in the presence of transport blocker lidocaine. Schematic figure for the axon isolation chamber are in Online Resource 3

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Fig. 7. Modulation of deimination affects visual function. **a** Schematic depiction of time line experiment of Pattern Electretinogram (PERG). PAD2 viral vectors intravitreal injection and lidocaine retrobulbar injection (cartoon on the left) were performed as indicated. **b** Evaluation PERG amplitudes in ND4(H) hybrid mice after 7 day of PAD2 overexpression in RGCs. Representative PERG signal from 2.5 month old ND4(H) mice. The control and viral vector mediated PAD2 expressing mice are as indicated. The pre- and post- lidocaine injection is shown in blue and red respectively. PERG was measured 10min after 4% lidocaine retrobulbar injection. Latency remains same (dashed line) but amplitude changes. **c** Mean $\pm$ SEM for PERG amplitude normalized to baseline for PAD2-expressing (+PAD2) and control mice post lidocaine injection (day 7th of PAD2 expression). ANOVA showed significant difference between the control and treated groups ($n=7$; $*p<0.005$). **d** Heidelberg optical coherence tomography imaging of RGC (Thy1) signal 1 week after PAD2 viral vector injection compared to control as indicated. Arrows indicate the Thy1 positive RGC cells. **e** Quantification of yellow fluorescent protein signal (Thy1) from comparative area (represented by boxed area in (D)) by Image J ($n=6$; $*p<0.005$).

Fig. 8.

Modulation of deimination affects protein expression in vivo. **a** Representative Western blot of protein expression in PAD2-expressing (+PAD2) and control retinas (n=3). Bottom panel is densitometric quantification of blots by ImageJ (n=3; *p<0.005). **b–d** Representative IHC of Thy 1, deimination, REF, SNAP-25, PAD2 in PAD2-expressing (+PAD2) and control retina as indicated. Bar=20μm. The merged image with DAPI staining has been shown in the first panel. **e** Schematic diagram of deimination mediated mRNA transport in neurons. REF and ANP32a are two mRNAs binding proteins that preferentially binds different mRNAs. They associate with each other in the soma and nucleus. When deiminated by PAD2 (indicated as green circle outline), the two proteins recruited the components of RNA granules such as eIFs and ribosomes, and facilitate the mRNAs (such SNAP-25, camk1) transport to different destinations

Selected interactors of PAD2

Table 1

Selected proteins from IP PAD2					
Function Classification	Protein name	Accession	Species	Unique peptide	Peptide number
Cytoskeleton	Protein-arginine deiminase type-2	Q9Y2J8	Human	10	11
	F-actin-capping protein subunit alpha-1	P47753	Mouse	3	4
	F-actin-capping protein subunit alpha-2	P47754	Mouse	4	5
	Microtubule-associated protein 1B	P14873	Mouse	7	8
Eukaryotic Translation	Dynactin subunit 2	Q6AYH5	Rat	1	1
	Tubulin beta-2A chain	Q13885	Human	1	8
	Eukaryotic translation initiation factor 3 subunit G	Q9Z1D1	Mouse	3	3
	Eukaryotic translation initiation factor 3 subunit B	Q4G061	Rat	3	3
Formation of ribosome	Eukaryotic translation initiation factor 4B	Q8BGD9	mouse	19	19
	40S ribosomal protein S14	P13471	Rat	1	3
	60S ribosomal protein L13	P41123	Rat	2	2
	60S ribosomal protein L14	Q9CR57	Mouse	2	2
	60S ribosomal protein L28	P41105	Mouse	1	1
	60S ribosomal protein L4	Q9D8E6	Mouse	2	3
	60S ribosomal protein L6	P47911	Mouse	1	1

Selected proteins from IP_PAD2						
Function Classification	Protein name	Accession	Species	Unique peptide	Peptide number	Peptide
Metabolism of protein	Caspase-9	Q8C3Q9	Mouse	1	1	DQARQLVTDLETRGR
Metabolism of mRNA	Putative RNA-binding protein 3	O89086	Mouse	1	1	YDSRPGGYGYGYGR
	Polyadenylate-binding protein 1-like	Q4VXU2	Human	1	2	FSPAGPILSIR, AILTQYMQRLSTMIR
	THO complex subunit 4	O08583	Mouse	2	2	QQLSAEELDAQLDAYNAR, SLGTADVHFER
	Ubiquitin-like protein 4A	P21126	Mouse	1	1	LVDSPATPIWQLISK

Table 2

Different interactors associates with REF/ANP32a in different cell compartment

Selected proteins from IP ANP32 neurites					
Protein name	Accession	Species	Peptide number	Unique peptide	Peptide
60S ribosomal protein L13	P47963	Mouse	2	1	STESLQANVQR, IAPRPASGPIRPVR
60S ribosomal protein L13a	P19253	Mouse	3	1	KVVVRCCEGINISGNFYR, RGQAALER, VVVVRCCEGINISGNFYR
60S ribosomal protein L15	Q9CZM2	Mouse	2	1	SLQSAEER, VLNSYWVGEDSTYKFFEVLIDPFHKAIR
60S ribosomal protein L18	P35980	Mouse	3	1	GTVLLSGPR, TNRPLSLSRMIR, TAVVVGTVTDDVR
60S ribosomal protein L31	Q1KSC7;P62900	Mouse	1	1	SAINEVVTR
Heat shock cognate 71 kDa protein	P63017	Mouse	3	2	TTPSYVAFDTTER, FEELNADLFR, DAGTIAGLNVLR
Tubulin alpha-1C chain	P68365;P68373	Mouse	8	6	TIGGGDDSFNTFFSETGAGK, AVFVDLEPTVIDEVR, LISQIVSSITASLR, EIIDLVLDR, DVNAAIATIK, FDGALNVDLTBEQTNLVPYPR, LSVDYGK, EDMAALEK
Tubulin beta-3 chain	Q9ERD7	Mouse	5	2	FPGQLNADLR, AILVDLEPMTDMSVR, YLTVAIVFR, ALTVPPELTQQMFDAK, MSMKEVDEQMLAIQSKNSSYFVEWIPNNVK
Tubulin beta-4B chain	P68372	Mouse	5	1	FPGQLNADLR, EVDEQMLNVQNK, ALTVPPELTQQMFDAK, IREEYPDR, MSATFIGNSTAIQELFK

Selected proteins from IP ANP32 cell body					
Protein name	Accession	Species	Peptide	Unique peptide	Peptide
Tubulin beta-2B chain	Q9CWF2	Mouse	12	4	GHYTEGAELVDSVLDVVR, AILVDLEPMTDMSVR, ISEQFTAMFR, FPGQLNADLR, MSATFIGNSTAIQELFK, ALTVPPELTQQMFDSK, IREEYPDR, EVDEQMLNVQNK, LHFFMPGFAPLTSR, YLTVAIVFR, INVYNEATGK, NSSYFVEWIPNNVK, ISEQFTAMFR
Tubulin beta-3 chain	Q9ERD7	Mouse	12	6	GHYTEGAELVDSVLDVVR, AILVDLEPMTDMSVR, ISEQFTAMFR, FPGQLNADLR, IMINTFSVVPSPK, ALTVPPELTQQMFDAK, YLTVAIVFR, EVDEQMLAIQSK, ISVYVNEASSHK, NSSYFVEWIPNNVK, MSSTFIGNSTAIQELFK, VREEYPDR
Ubiquitin-40S ribosomal protein S27a	P62983	Mouse	2	1	ECPSDECGAGVFMGSHFDR, TITLVEPSDTIENVKAK
40S ribosomal protein S6	P62754	Mouse	1	1	IPDWFLNR
60S ribosomal protein L19	P84099	Mouse	2	1	STESLQANVQR, VDTWFNQPAK
60S ribosomal protein L18	P12001	Rat	2	2	TAVVVGTTDDVR, GTVLLSGPR
60S ribosomal protein L13	P47963	Mouse	2	1	LLADQAEAR, DGLIRKPKVTVHSR
Heat shock 70 kDa protein 1-like	P16627	Mouse	3	2	TTPSYVAFDTTER, VEIANDQGNR, TLLSSSTQANLEISLYEGIDFYTSITRAR
40S ribosomal protein S18	P62270	Mouse	1	1	LIEVDDER
Heat shock protein HSP 90-beta	P11499	Mouse	2	1	GVVDSDELPLNISR, YIDQEELNK
mRNA export factor	Q8C570	Mouse	1	1	NAAEELKPR

Selected proteins from IP_ANP32 cell body					
Protein name	Accession	Species	Peptide	Unique peptide	Peptide
E3 ubiquitin-protein ligase UBR5	Q80TP3	Mouse	6	1	NSLEDLTAEDFR, SSAGARDSRR, SRSVIRELQR, VDGAYVAVK, NRGERDR, SLRLREMMR

Selected proteins from IP_REF neurites					
Protein name	Accession	Species	Peptide number	Unique peptide	Peptides
E3 ubiquitin-protein ligase XIAP	Q60989	Mouse	2	1	NPEAPDRPPETHADYLLR, RISPNCR
Tubulin alpha-1A chain	P68362;P68369	Mouse	5	1	AVFVDLEPTVIDEVR, EIIDLVLDR, DVNAAIATIK, LIGQIVSSITASLR, NLDIERPTYTNLNR
Tubulin alpha-1C chain	P68365;P68373	Mouse	5	1	AVFVDLEPTVIDEVR, EIIDLVLDR, LISQIVSSITASLR, DVNAAIATIK, NLDIERPTYTNLNR
Tubulin beta-2A chain	Q7TMM9	Mouse	6	5	AILVDLEPGTMDSVR, FPGQLNADLR, EVDEQMLNVQNK, YLTVAAIIFR, GHYTEGAELVDSVLDVVR, IREEYPDR

Selected proteins from IP_REF cell body					
Protein name	Accession	Species	Peptide number	Unique peptide	Peptide
40S ribosomal protein S13	P62301	Mouse	1	1	GLSQSALPYR
40S ribosomal protein S15a	P62245	Mouse	1	1	MNVLADALK
40S ribosomal protein S18	P62270	Mouse	1	1	IPDWFLNR
40S ribosomal protein S3	P62908	Mouse	3	1	TPVEPEVAIHR, TPCGEGSKTWDRFQMR, SLEKVCADLR
60S ribosomal protein L13	P47963	Mouse	2	2	STESLQANVQR, GFSLEELR
60S ribosomal protein L27	P61358	Mouse	1	1	YSVDIPLDK
60S ribosomal protein L6	P47911	Mouse	1	1	YYPTEDVPR
60S ribosomal protein L7a	P12970	Mouse	4	1	VPPAINQFTQALDR, TCTTVAFTQVNSDKGALAK, VVNPLFEKRPK, YDEIRRHWWGGNVLGPK
Heat shock-related 70 kDa protein 2	P17156	Mouse	1	1	TTPSYVAFTDTER
Tubulin alpha-1A chain	P68362;P68369	Mouse	2	2	LIGQIVSSITASLR, DVNAAIATIK
Tubulin beta-2B chain	Q9CWF2	Mouse	9	8	GHYTEGAELVDSVLDVVR, AILVDLEPGTMDSVR, FPGQLNADLR, LAVNMVPPFR, LHFEMPGEAPLTSR, INVYYNEATGK, EVDEQMLNVQNK, IREEYPDR, ISEQFTAMFR
Caspase-9	Q8C3Q9	Mouse	1	1	DQARQLVTDLETRGR
Elongation factor 1-alpha 1	P62629;P10126	Mouse	7	2	STTTGHLIYK, LPLQDVYK, THINIVVIGHVDSGK, EHALLAYTLGVK, QLIVGVNK, STTTGHLIYKCGGIDK, EAAEMGKGSFK